v3.24.2.u1
Investments and Other Assets - Additional Information (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]            
Reclassification of other comprehensive loss - equity method investment   $ 2,132,000        
Investments and other assets $ 49,835,000     $ 49,835,000   $ 42,883,000
Change in fair value of investments, net (20,354,000)   $ 0 (26,419,000) $ 0  
Collaboration revenue 6,957,000   13,594,000 35,892,000 26,200,000  
Accrued expenses 45,127,000     45,127,000   67,017,000
AvenCell Therapeutics, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Reclassification of other comprehensive loss - equity method investment       2,100,000    
Investments and other assets 9,600,000     9,600,000    
Kyverna Therapeutics Inc [Member]            
Schedule of Equity Method Investments [Line Items]            
Investment Owned, Balance, Principal Amount 800,000     800,000    
Change in fair value of investments, net 20,400,000     1,200,000    
Investment Owned, Fair Value           10,000,000
Collaboration revenue 0     0    
AvenCell [Member]            
Schedule of Equity Method Investments [Line Items]            
Change in fair value of investments, net       25,300,000    
Investment Owned, Fair Value           11,800,000
Collaboration revenue     5,800,000 21,000,000 10,700,000  
Accounts receivable 200,000     200,000   200,000
Accrued expenses $ 1,000,000     $ 1,000,000   $ 1,000,000
AvenCell [Member] | AvenCell Therapeutics, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity method investment, ownership percentage 33.33%     33.33%   33.33%
Collaboration revenue       $ 0    
Sparing Vision [Member]            
Schedule of Equity Method Investments [Line Items]            
Investment Owned, Fair Value $ 14,600,000     14,600,000    
Collaboration revenue $ 500,000   $ 500,000 $ 1,100,000 $ 900,000